BEIT is building a hybrid classical-quantum computational chemistry platform for early-stage drug discovery. Drug discovery teams still rely on molecular modelling tools that are either fast but approximate, or accurate but too computationally expensive to use at scale. This creates a major bottleneck before synthesis: teams must choose which molecules to make, test, and optimize while working with limited confidence in binding, selectivity, free energy, and complex molecular interactions. BEIT addresses this gap by combining scalable GPU/HPC workflows with higher-accuracy electronic structure analysis and quantum-inspired optimization methods. Our platform is designed to improve the fidelity of molecular simulations while remaining deployable on today’s classical infrastructure—not dependent on future quantum hardware. The platform supports key molecular modelling workflows including docking, rescoring, free energy calculations, covalent binding, and larger biomolecular interactions. Instead of offering a single point solution, BEIT is building a unified computational infrastructure layer that can help pharma, biotech, and AI drug discovery companies prioritize better molecules earlier, reduce wasted experimental work, and improve the economics of discovery. BEIT’s approach is quantum-ready, not quantum-dependent: customers can access value on current GPU/HPC infrastructure today, while the architecture remains compatible with future quantum processors as they mature. In short, BEIT brings physics-grade molecular modelling into scalable production software for drug discovery.